Despite PPT1 being a promising target for HCC tumors with relatively abundant metabolism alternations, these findings supported that the therapy strategy in a metabolic subtype-specific manner might be more efficient than those trying to cover all patients. The gene discussed is PPT1; the disease is hepatocellular carcinoma.